Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”-Reference-Cited by-同舟云学术

Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”

Published:2023-09-14 Issue:6 Volume:12 Page:2195-2197
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Nieto-Gómez Pelayo^ORCID,Castaño-Amores Celia^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-023-00537-x.pdf

Reference6 articles.

1. Lager B, Liseno J, Božin I, et al. Real-World analysis affirms the high persistence and adherence observed with diroximel fumarate in patients with multiple sclerosis. Neurol Ther. 2023;12:145–59. https://doi.org/10.1007/s40120-022-00413-0.

2. Palte MJ, Wehr A, Tawa M, et al. Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study. Adv Ther. 2019;36(11):3154–65. https://doi.org/10.1007/s12325-019-01085-3.

3. Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, doubleblind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185–96. https://doi.org/10.1007/s40263-020-00700-0.

4. European Medicines Agency. European public assessment report of vumerity. https://www.ema.europa.eu/en/medicines/human/EPAR/vumerity. Accessed 15 June 2023

5. Araujo L, Geertsen SS, Amedume A, Higuchi K, van Wingerden J. Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study. Neurol Ther. 2022;11(4):1735–48. https://doi.org/10.1007/s40120-022-00404-1.